FDA Grants First-Line Approval for Enhertu Combination in HER2-Positive Breast Cancer
The U.S. Food and Drug Administration has approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (fam-trastuzumab deruxtecan) in combination with […]